Tisotumab Biosimilar – Anti-F3 , CD142 mAb – Research Grade

Tisotumab Biosimilar: A Novel Anti-F3, CD142 mAb for Targeted Therapy

Tisotumab Biosimilar is a monoclonal antibody (mAb) that specifically targets the F3/CD142 protein, also known as tissue factor (TF). This protein is overexpressed in various types of cancer cells and plays a crucial role in tumor growth, angiogenesis, and metastasis. Tisotumab Biosimilar has been designed to bind to F3/CD142 with high affinity and inhibit its activity, making it a promising therapeutic option for cancer treatment.

Structure of Tisotumab Biosimilar

Tisotumab Biosimilar is a recombinant humanized IgG1 antibody, meaning it is derived from both human and non-human sources. Its structure consists of two heavy chains and two light chains, connected by disulfide bonds. The heavy and light chains each contain a variable region, responsible for binding to the target protein, and a constant region, which determines the antibody’s effector functions.

The variable region of Tisotumab Biosimilar has been engineered to specifically recognize and bind to the extracellular domain of F3/CD142. This region is highly conserved among different cancer types, making Tisotumab Biosimilar a potential therapeutic option for a wide range of cancers.

Mechanism of Action

Once bound to F3/CD142, Tisotumab Biosimilar blocks the interaction between F3/CD142 and its ligands, including coagulation factors and growth factors. This inhibits the activation of downstream signaling pathways involved in tumor growth and angiogenesis. Tisotumab Biosimilar also triggers antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to the destruction of cancer cells.

Moreover, Tisotumab Biosimilar has been shown to induce antibody-dependent cellular phagocytosis (ADCP), where immune cells engulf and digest cancer cells bound by the antibody. This mechanism further enhances the anti-tumor effects of Tisotumab Biosimilar.

Applications of Tisotumab Biosimilar

As a targeted therapy, Tisotumab Biosimilar has shown promising results in pre-clinical and clinical studies for the treatment of various types of cancer, including ovarian, cervical, and lung cancer. In a phase I/II clinical trial, Tisotumab Biosimilar demonstrated anti-tumor activity in patients with recurrent or metastatic cervical cancer, with manageable side effects.

Furthermore, Tisotumab Biosimilar has also shown potential in combination therapy with other anti- cancer drugs. A pre-clinical study showed that Tisotumab Biosimilar, when combined with a chemotherapy drug, significantly reduced tumor growth in a mouse model of ovarian cancer. This suggests that Tisotumab Biosimilar could enhance the efficacy of chemotherapy and potentially reduce its toxicity.

Conclusion

Tisotumab Biosimilar is a novel anti-F3, CD142 mAb with a unique mechanism of action and promising therapeutic potential. Its specific targeting of F3/CD142 makes it a promising option for the treatment of various types of cancer. Further clinical trials are needed to fully evaluate the efficacy and safety of Tisotumab Biosimilar, but its potential as a targeted therapy for cancer is highly encouraging.

Keywords: Tisotumab Biosimilar, monoclonal antibody, F3/CD142, tissue factor, targeted therapy, cancer treatment, anti-tumor activity, combination therapy